Drugs / Citarinostat
Trials 5 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02886065 | Mar 2017 → Sep 2026 expected | smoldering plasma cell myeloma | Massachusetts General Hospital | Active not recruiting | No outcome recorded |
| Phase 1 | NCT02935790 | Sep 2016 → Apr 2017 | melanoma | Celgene Corporation | Completed | No outcome recorded |
| Phase 1 | NCT02635061 | Aug 2016 → Jan 2024 | non-small cell lung carcinoma | Celgene Corporation | Terminated | No outcome recorded |
| Phase 1 | NCT02551185 | Dec 2015 → Sep 2019 | cancer | Celgene Corporation | Completed | No outcome recorded |
| Phase 1 | NCT02400242 | May 2015 → Jun 2024 | plasma cell myeloma | Celgene Corporation | Terminated | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Citarinostat | “Selective Histone Deacetylase Inhibitor ACY-241 (Citarinostat) Plus Nivolumab in Advanced Non-Small Cell Lung Cancer: Results From a Phase Ib Study.” PMID 34552864 ↗ Sep 20212“Citarinostat (CC-96241; previously ACY-241), an oral inhibitor of histone deacetylases (HDACs) with selectivity for HDAC6” PMID 35070991 ↗ Jan 2022 |
| Known as | ACY-241 | “Citarinostat (CC-96241; previously ACY-241), an oral inhibitor of histone deacetylases (HDACs) with selectivity for HDAC6” PMID 35070991 ↗ Jan 2022 |
| Known as | CC-96241 | “Citarinostat (CC-96241; previously ACY-241), an oral inhibitor of histone deacetylases (HDACs) with selectivity for HDAC6” PMID 35070991 ↗ Jan 2022 |
| Known as | HDAC-IN-2 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3693786 ↗ |
| Action | Inhibit | “Histone deacetylase inhibitor” NCT02400242 ↗ |
| Modality | Small molecule | “Citarinostat is an orally active, small-molecule Histone Deacetylase (HDAC) Inhibitor” NCT02886065 ↗ |
| Route | Oral | “oral ACY-241” NCT02400242 ↗ |
| Target | HDAC6 | “with selectivity for HDAC6” PMID 35070991 ↗ Jan 2022 |